TWST
Twist Bioscience Corporation
NASDAQ · USHealthcareMedical - Diagnostics & Research
$87.45-6.82%
Price as of Jul 20, 2026
TWST financials
Twist Bioscience Corporation financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $376.6M | $313.0M | $245.1M | $203.6M |
| Cost of revenue | $185.6M | $179.6M | $155.4M | $119.3M |
| Gross profit | $191.0M | $133.3M | $89.7M | $84.2M |
| Operating expenses | $327.3M | $354.2M | $306.9M | $319.0M |
| Operating income | -$136.3M | -$220.8M | -$217.2M | -$234.8M |
| Net income | -$77.7M | -$208.7M | -$204.6M | -$217.9M |
| EBITDA | -$52.1M | -$176.7M | -$174.2M | -$211.7M |
| Basic EPS | $-1.30 | $-3.60 | $-3.60 | $-4.04 |
| Diluted EPS | $-1.30 | $-3.60 | $-3.60 | $-4.04 |
| Balance sheet | ||||
| Cash & equivalents | $183.0M | $226.3M | $286.5M | $378.7M |
| Total assets | $641.9M | $614.3M | $776.4M | $961.4M |
| Total liabilities | $168.9M | $141.6M | $153.0M | $172.0M |
| Stockholders’ equity | $473.0M | $472.7M | $623.4M | $789.4M |
| Total debt | $137.3M | $85.0M | $94.1M | $94.9M |
| Net debt | -$45.7M | -$141.3M | -$192.4M | -$283.8M |
| Cash flow | ||||
| Operating cash flow | -$47.6M | -$64.1M | -$142.5M | -$124.4M |
| Capital expenditure | -$28.0M | -$5.1M | -$27.8M | -$101.9M |
| Free cash flow | -$75.6M | -$69.2M | -$170.3M | -$226.2M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | -$16.0K | -$4.0M | -$4.4M | -$7.8M |